FLUORESCEIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fluorescein Sodium, and when can generic versions of Fluorescein Sodium launch?
Fluorescein Sodium is a drug marketed by Nexus Pharms and Bausch Lomb Ireland and is included in two NDAs. There are three patents protecting this drug.
The generic ingredient in FLUORESCEIN SODIUM is benoxinate hydrochloride; fluorescein sodium. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the benoxinate hydrochloride; fluorescein sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Fluorescein Sodium
Indicators of Generic Entry
Summary for FLUORESCEIN SODIUM
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Clinical Trials: | 42 |
| Patent Applications: | 50 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | FLUORESCEIN SODIUM at DailyMed |
Recent Clinical Trials for FLUORESCEIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Early Phase 1 |
| Seoul National University Bundang Hospital | Phase 4 |
| Eximore Ltd. | Phase 1 |
Pharmacology for FLUORESCEIN SODIUM
| Drug Class | Diagnostic Dye |
| Mechanism of Action | Dyes |
Medical Subject Heading (MeSH) Categories for FLUORESCEIN SODIUM
Anatomical Therapeutic Chemical (ATC) Classes for FLUORESCEIN SODIUM
US Patents and Regulatory Information for FLUORESCEIN SODIUM
FLUORESCEIN SODIUM is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting FLUORESCEIN SODIUM
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Try a Trial
